Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required ...

Adding erythropoietin to hydroxyurea treatment could significantly improve quality of life for patients with sickle cell ...

Uganda is among the countries with the highest burden of the disease, with an estimated 33,000 babies born each year carrying the sickle cell trait or disease ...

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...

The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...

Fulcrum Therapeutics ( FULC) on Saturday reported positive initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.

Dr Oscar Mugerwa, an attending physician at the same health facility, said Jayden no longer responds to hydroxyurea, and a bone marrow transplant is now the best chance to significantly improve his ...

The safety profile remained consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying SCD. The most common treatment-emergent adverse events included ...

Presented new data in non-human primates (NHP) for sickle cell disease (SCD), where RNA Gene Writer achieved approximately 40% and 60% of long-term hematopoietic stem cells (LT-HSCs) with at least one ...

Investing.com -- Fulcrum Therapeutics (NASDAQ:FULC) stock surged 50% Monday after the company reported positive initial results from its Phase 1b PIONEER trial of pociredir in sickle cell disease ...

Thalassemia and other haemoglobin disorders often remain undiagnosed without proper testing. Experts stress the need for premarital and genetic screening to detect carriers early, prevent severe cases ...